Jakafi 10 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DR26FHGS9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,730
Award facts
- Contract value 100% obligated
- $24,729.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,729.64 to DMS Pharmaceutical Group Inc. for JAKAFI 10 mg tablets (60-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation under a firm fixed-price contract structure. The delivery order represents a single transaction issued under the company's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract with DLA, which carries a $500 million ceiling and extends through December 31, 2036.
This delivery order is part of DMS Pharmaceutical Group's established role as a critical regional pharmaceutical supplier within DLA's $30.3 billion PPV-G GEN V acquisition strategy, which was recently awarded on November 13, 2025. The company supplies a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally. No subcontractors have been identified in the award documentation, and DLA's Medical Supply Chain division serves as the funding federal agency. The company's demonstrated performance across numerous prior delivery orders and its established distribution capabilities position it to fulfill specialized pharmaceutical requirements for military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FHGS9?
SPE2DR26FHGS9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FHGS9 worth?
The government has obligated $24,730 on SPE2DR26FHGS9.
Is contract SPE2DR26FHGS9 an order under another contract?
Yes. SPE2DR26FHGS9 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGS9 competed?
The extent of competition for SPE2DR26FHGS9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award